Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECTOR: Solifenacin vs Oxybutynin for OAB
NCT00431041Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2006
- Primary completion
- Feb 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of solifenacin in overactive bladder (OAB), sponsored by Astellas Pharma. Started Dec 2006; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00431041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431041.